Black Women Screen Most, Die Most: The Breast Cancer Gap

The Commonwealth Fund's 2026 State Health Disparities Report, released in April 2026, found that in 37 of the 40 states with usable data, Black women had the highest breast cancer death rate, even though they got mammograms at high rates. The report ties the pattern to delays in follow-up care after an abnormal mammogram, to cancers caught at later stages, and to insurance that covers the screening but not always the testing that comes next.

The screening numbers back this up. In 2022, Black women aged 50 to 74 reported the highest mammography use of any group, with 82.9 percent screened in the previous two years, and Black women aged 40 to 49 led their age band too, at 65.2 percent, according to a CDC Vital Signs analysis published in 2024. Black women are showing up for the test. The system is failing them after it.

That 40 percent gap is not driven by Black women getting more breast cancer. American Cancer Society data from 2016 to 2020 show Black women have a 4 percent lower incidence of breast cancer than white women, yet the higher death rate. For women under 50 the gap is worse: Black women in that age group die at roughly twice the rate of white women the same age. Black women also have the lowest five-year survival for every breast cancer subtype and for every stage except localized disease, which they are less likely to be diagnosed with in the first place.

An abnormal screening mammogram is not a diagnosis. It is a flag that something needs a closer look, usually a diagnostic mammogram or ultrasound, and sometimes a biopsy. The clock that matters for survival starts here, and it runs slower for Black women at every step.

A 2024 study in JCO Oncology Practice by Ritika Manik and colleagues found Black women waited 1.75 times as long as white women to get a tissue diagnosis after an abnormal screen. Median time from screening to diagnostic imaging was 12 days for Black women versus 7 for white women, and from diagnostic imaging to biopsy, 21 days versus 12. After adjustment, Black women had 41 percent lower odds of getting diagnostic imaging within 15 days of the screen. A separate 2023 study in the Journal of Breast Imaging by Sora Yoon and colleagues found that even a same-day biopsy program, which cut wait times overall, shortened them significantly for white women but not for Black women.

The delay continues into treatment. In the Carolina Breast Cancer Study, Katherine Reeder-Hayes of the UNC Lineberger Comprehensive Cancer Center found Black women had 1.73 times higher odds of starting treatment more than 60 days after diagnosis. In a later population-based study of more than 32,000 North Carolina patients, 15.0 percent of Black patients faced treatment delays beyond 60 days, compared with 8.0 percent of others, and the higher risk held in every clinical subgroup. Reeder-Hayes connected those delays directly to the death gap, writing that treatment delays "have been linked consistently to higher recurrence and mortality risk, suggesting that delays play a role in persistent racial gaps in breast cancer mortality."

The Affordable Care Act requires insurers to cover screening mammograms with no out-of-pocket cost. It does not extend that protection to diagnostic follow-up. When a radiologist needs more views, an ultrasound, an MRI, or a biopsy to read an abnormal screen, that imaging is often billed as diagnostic and can carry a copay, coinsurance, or the full cost against a deductible. The Commonwealth Fund report names this gap as one reason Black women, who carry higher rates of being uninsured or underinsured, fall behind after the screen even when they show up for it.

States have started closing the gap. By 2024 roughly 20 states had passed laws barring cost-sharing for diagnostic and supplemental breast imaging. Maine's 2023 law bans cost-sharing on screening, diagnostic, and supplemental exams. Washington's law applies to plans issued or renewed on or after January 1, 2024. Pennsylvania's Act 1 of 2023 covers supplemental MRI and ultrasound for higher-risk patients, with a 2025 law phasing in zero out-of-pocket diagnostic imaging by 2028. These laws generally reach state-regulated plans, not self-funded employer plans governed by federal ERISA rules, so coverage depends on your state and your specific plan.

Black women are diagnosed with triple-negative breast cancer at far higher rates than white women, a subtype that grows fast, lacks the hormone and HER2 targets that many drugs rely on, and carries a worse prognosis. Research summarized by Breastcancer.org puts the risk of triple-negative disease at nearly three times higher for Black women than white women. When the most aggressive form of the disease is also the one more likely to land on a Black woman's chart, the weeks lost to follow-up and treatment delays carry more weight, not less. This is part of why earlier detection matters so much for this group, and why the 2024 USPSTF decision to lower the screening start age to 40 was modeled in part on averting more deaths among Black women.

The screening is the easy part now. Protecting yourself means managing what happens after it. When a screen is abnormal, ask three questions in the room or on the phone: when is my diagnostic appointment, will this be billed as screening or diagnostic, and who is tracking that I actually get the next step. Knowing whether your follow-up imaging carries cost-sharing lets you check your state's diagnostic-coverage law and push back on a surprise bill before it stops you from going. If a biopsy is ordered, get the date in writing and a contact for results.

Care from a clinician who takes your symptoms seriously and moves fast changes outcomes. You can find a Black OB-GYN, primary care doctor, or breast specialist in our directory who serves Black patients and will not slow-walk your follow-up. For more on the subtype that drives much of this gap, read our explainer on triple-negative breast cancer in Black women, and on why showing up for the screen still matters, see our piece on Tina Knowles, breast cancer, and Black women's screening.